Grantham, Mayo, Van Otterloo & Co (GMO)’s Vanda Pharmaceuticals VNDA Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$173K	Buy	28,344 +12,022	+74%	+$78.5K	﹤0.01%	650
2026 Q1	$113K	Buy	+16,322	New	+$126K	﹤0.01%	621
2021 Q4	–	Sell	-13,100	Closed	-$225K	–	739
2021 Q3	$225K	Buy	+13,100	New	+$229K	﹤0.01%	661
2021 Q1	–	Sell	-14,600	Closed	-$192K	–	945
2020 Q4	$192K	Sell	14,600 -122,700	-89%	-$1.48M	﹤0.01%	780
2020 Q3	$1.33M	Sell	137,300 -29,300	-18%	-$313K	0.01%	471
2020 Q2	$1.91M	Buy	166,600 +146,600	+733%	+$1.66M	0.01%	428
2020 Q1	$207K	Buy	+20,000	New	+$248K	﹤0.01%	700

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s VNDA Position: Q2 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) increased its Vanda Pharmaceuticals (VNDA) stake by 74% in Q2 2026, buying an estimated $78.5K and bringing the position to 28,344 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #650.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in VNDA in Q1 2020 and has held it in 7 quarters since. The position peaked at $1.91M in Q2 2020. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Grantham, Mayo, Van Otterloo & Co (GMO) held 28,344 shares of Vanda Pharmaceuticals worth $173K as of Q2 2026.
Grantham, Mayo, Van Otterloo & Co (GMO) bought 12,022 Vanda Pharmaceuticals shares in Q2 2026, an estimated $78.5K.
Vanda Pharmaceuticals made up ﹤0.01% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q2 2026, its #650 holding.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Vanda Pharmaceuticals in Q1 2020 and has held it in 7 quarters since.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Vanda Pharmaceuticals position peaked at $1.91M in Q2 2020.
173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2026, filed 13 Aug 2026.